Table 2 List of factors examined
From: Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery
All patients (n = 23) | Transient PSA elevation (n = 11) | PSA decline (n = 12) | p-value | |
|---|---|---|---|---|
Recurrent cases | 12 (52.2%) | 6 (54.5%) | 6 (50%) | 0.837 |
Time to recurrence after salvage RT (months) | 0.593 | |||
Median | 26 | 21 | 26 | |
Range | 2–55 | 7–55 | 2–29 | |
Period from post-operation to RT (months) | 0.742 | |||
Median | 14 | 11 | 18.5 | |
Range | 3–65 | 4–65 | 3–44 | |
Pre-RT PSA (ng/ml) | 0.089 | |||
Median | 0.32 | 0.41 | 0.28 | |
Range | 0.1–1.77 | 0.1–1.77 | 0.19–0.61 | |
PSADT (day) | 0.037 | |||
Median | 129.1 | 63.16 | 254.1 | |
Range | 22.8–471.1 | 28.8–257 | 38.9–471.1 | |
PSAV (ng/ml/year) | 0.071 | |||
Median | 0.65 | 1.1 | 0.172 | |
Range | 0.086–6.74 | 0.102–6.74 | 0.086–1.648 | |
Transient PSA elevation value (ng/ml) | ||||
Median | 0.12 | |||
Range | 0.01–0.37 | |||
Decline in PSA value (ng/ml) | ||||
Median | 0.07 | |||
Range | 0.02–0.25 | |||
Dose at PSA measurement (Gy) | 0.281 | |||
Median | 36 | 24 | 37 | |
Range | 10–60 | 10–60 | 20–66 |